Eli Lilly's transpacific bosom buddy Terns bags late-round funding to drive NASH hopefuls through the clinic

In a hot market market for NASH, having big-name backers can help shine a spotlight on startup players looking to make a mark. That was certainly the case for Terns Pharmaceuticals and partner Eli Lilly, which provided seed funding and licensed three NASH candidates to the baby biotech back in 2018.